Literature DB >> 16701520

In vitro activity of ramoplanin and comparator drugs against anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.

Sydney M Finegold1, Shahera St John, Ann W Vu, Calida M Li, Denise Molitoris, Yuli Song, Chengxu Liu, Hannah M Wexler.   

Abstract

Susceptibility of intestinal bacteria to various antimicrobial agents in vitro, together with levels of those agents achieved in the gut, provides information on the likely impact of the agents on the intestinal flora. Orally administered drugs that are poorly absorbed may be useful for treatment of intestinal infections and for certain other situations in which intestinal bacteria may play a role. The antimicrobial activity of ramoplanin (MDL 62,198) against 928 strains of intestinal anaerobic bacteria was determined using the NCCLS-approved Wadsworth brucella laked-blood agar dilution method. The activity of ramoplanin was compared with that of ampicillin, bacitracin, metronidazole, trimethoprim/sulfamethoxazole (TMP/SMX), and vancomycin. The organisms tested included Bacteroides fragilis group (n=89), other Bacteroides species (n=16), other anaerobic Gram-negative rods (n=56) anaerobic cocci (n=114), Clostridium species (n=426), and non-sporeforming anaerobic Gram-positive rods (n=227). The overall MIC(90)s of ramoplanin, ampicillin, bacitracin, metronidazole, and vancomycin were 256, 32, 128, 16, and 128 mcg/ml, respectively. Ramoplanin was almost always highly active vs. Gram-positive organisms and relatively poor in activity against Gram-negative organisms, particularly Bacteroides, Bilophila, Prevotella, and Veillonella. Vancomycin was quite similar to ramoplanin in its activity. Ampicillin was relatively poor in activity vs. organisms that often produce beta-lactamase, including most of the Gram-negative rods as well as Clostridium bolteae and C. clostridioforme. Bacitracin was relatively poor in activity against most anaerobic Gram-negative rods, but better vs. most Gram-positive organisms. Metronidazole was very active against all groups other than bifidobacteria and some strains of other types of non-sporeforming Gram-positive bacilli. TMP/SMX was very poorly active, with an MIC(90) of >2048 mcg/ml.

Entities:  

Year:  2004        PMID: 16701520     DOI: 10.1016/j.anaerobe.2004.04.003

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  9 in total

Review 1.  Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.

Authors:  Dhara Shah; Minh-Duc Dang; Rodrigo Hasbun; Hoonmo L Koo; Zhi-Dong Jiang; Herbert L DuPont; Kevin W Garey
Journal:  Expert Rev Anti Infect Ther       Date:  2010-05       Impact factor: 5.091

2.  Reduced diversity and imbalance of fecal microbiota in patients with ulcerative colitis.

Authors:  Hideyuki Nemoto; Keiko Kataoka; Hideki Ishikawa; Kazue Ikata; Hideki Arimochi; Teruaki Iwasaki; Yoshinari Ohnishi; Tomomi Kuwahara; Koji Yasutomo
Journal:  Dig Dis Sci       Date:  2012-05-24       Impact factor: 3.199

Review 3.  Future novel therapeutic agents for Clostridium difficile infection.

Authors:  Hoonmo L Koo; Kevin W Garey; Herbert L Dupont
Journal:  Expert Opin Investig Drugs       Date:  2010-07       Impact factor: 6.206

4.  Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.

Authors:  Diane M Citron; Kerin L Tyrrell; C Vreni Merriam; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

5.  Generation of ramoplanin-resistant Staphylococcus aureus.

Authors:  John W Schmidt; Adrienne Greenough; Michelle Burns; Andrea E Luteran; Dewey G McCafferty
Journal:  FEMS Microbiol Lett       Date:  2010-07-02       Impact factor: 2.742

6.  Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection.

Authors:  Milagros Gonzales; Jacques Pepin; Eric H Frost; Julie C Carrier; Stephanie Sirard; Louis-Charles Fortier; Louis Valiquette
Journal:  BMC Infect Dis       Date:  2010-12-30       Impact factor: 3.090

7.  Comparative genomics of Clostridium bolteae and Clostridium clostridioforme reveals species-specific genomic properties and numerous putative antibiotic resistance determinants.

Authors:  Pierre Dehoux; Jean Christophe Marvaud; Amr Abouelleil; Ashlee M Earl; Thierry Lambert; Catherine Dauga
Journal:  BMC Genomics       Date:  2016-10-21       Impact factor: 3.969

8.  Production of Ramoplanin and Ramoplanin Analogs by Actinomycetes.

Authors:  Mercedes de la Cruz; Ignacio González; Craig A Parish; Russell Onishi; José R Tormo; Jesús Martín; Fernando Peláez; Debbie Zink; Noureddine El Aouad; Fernando Reyes; Olga Genilloud; Francisca Vicente
Journal:  Front Microbiol       Date:  2017-03-06       Impact factor: 5.640

9.  Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencing.

Authors:  Dea Shahinas; Michael Silverman; Taylor Sittler; Charles Chiu; Peter Kim; Emma Allen-Vercoe; Scott Weese; Andrew Wong; Donald E Low; Dylan R Pillai
Journal:  MBio       Date:  2012-10-23       Impact factor: 7.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.